Novartis, Roche find 'outcome-based' drug pricing an elusive dream

ZURICH (Reuters) - News that Novartis's heart drug Entresto cuts the risk of re-hospitalization might have helped Chief Executive Joe Jimenez realize his ambition of getting insurers to pay more for treatments when they cut overall medical costs.